LeMaitre Vascular, Inc.
LMAT Healthcare Medical Instruments & Supplies
LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- −14.3%
- Free cash flow
- −25.8%
- Total debt
- +0.53%
Quarter to September 2026, against a year earlier
Follow LMAT
Alert me
LeMaitre Vascular, Inc. (LMAT) P/B ratio
As of 5 November 2026, LeMaitre Vascular, Inc. (LMAT) trades at a P/B ratio of 4.4×. Over the past ten years it has ranged from 1.8× (January 2015) to 7.5× (September 2017); the current reading is higher than 42% of that period. That is above the Medical Instruments & Supplies industry median of 2.3× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.7× | (23.93%) |
| FY2024 | 6.1× | 45.02% |
| FY2023 | 4.2× | 13.62% |
| FY2022 | 3.7× | (10.98%) |
| FY2021 | 4.2× | (12.00%) |
| FY2020 | 4.8× | (1.18%) |
| FY2019 | 4.8× | 36.35% |
| FY2018 | 3.5× | (34.40%) |
| FY2017 | 5.4× | 0.85% |
| FY2016 | 5.3× | 35.47% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 4.4× | (16.23%) |
| Jun 2026 | 5.2× | (14.76%) |
| Mar 2026 | 6.1× | 31.21% |
| Dec 2025 | 4.7× | (10.85%) |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| AZTA Azenta, Inc. compare | 1.1× |
| XRAY DENTSPLY SIRONA Inc. compare | 1.5× |
| STVN Stevanato Group S.p.A. compare | 2.0× |
| STAA STAAR Surgical Company compare | 3.6× |
| LMAT LeMaitre Vascular, Inc. | 4.4× |
| ATRC AtriCure, Inc. compare | 5.6× |
| KMTS Kestra Medical Technologies, Ltd. compare | 7.4× |
| WRBY Warby Parker Inc. compare | 8.1× |
| PLSE Pulse Biosciences, Inc compare | 20.8× |
| Medical Instruments & Supplies industry median | 2.3× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on LMAT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement